HARBOUR BIOMED

和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION (the "NMPA") GRANTED APPROVAL OF THE INVESTIGATIONAL NEW DRUG ("IND") APPLICATION FOR COMBINATION THERAPY OF HBM4003, A NEXT-GENERATION, FULLY HUMAN ANTI-CTLA-4 ANTIBODY FOR TREATMENT OF NON-SMALL CELL LUNG CANCER ("NSCLC") AND SOLID TUMORS

This announcement is made by HBM Holdings Limited, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the NMPA of the People's Republic of China ("**China**" and for the purpose of this announcement only, excluding Hong Kong, Macau and Taiwan) has granted approval of the Group's IND application for HBM4003, a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with programmed cell death protein 1 (PD-1) antibody with or without chemotherapy in patients with advanced NSCLC and other solid tumors.

The Group has obtained an IND approval from the U.S. Food and Drug Administration and an IND approval from the NMPA in China, each for conducting a Phase 1 trial for HBM4003 as a monotherapy in advanced solid tumors. The Group has also obtained an IND approval from the NMPA for HBM4003 for another combination therapy. The Group has commenced ongoing Phase 1 study in Australia.

About HBM4003

HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. HBM4003 shows enhanced antibody-dependent cell cytotoxicity (ADCC) killing activity and is extremely specific to CTLA-4(high) Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect present a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug.

Cautionary Statement: we cannot guarantee that we will be able to develop, or ultimately market, HBM4003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 26 February 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang, Dr. Mai-Jing Liao, and Dr. Atul Mukund Deshpande as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.